# Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

> **NCT07030257** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tasca Therapeutics** · enrollment: 150 (estimated)

## Conditions studied

- Solid Tumor Malignancies
- Colorectal Carcinoma
- Small Cell Lung Cancer ( SCLC )
- Head and Neck (HNSCC)
- Bladder Cancer
- Non-Small Cell Lung Cancer
- Pancreatic Cancer, Advanced or Metastatic

## Interventions

- **DRUG:** CP-383

## Key facts

- **NCT ID:** NCT07030257
- **Lead sponsor:** Tasca Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-27
- **Primary completion:** 2028-08-15
- **Final completion:** 2029-02
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07030257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07030257, "Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07030257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*